$Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy$

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or progression remains a significant challenge. In this study, we p...

Full description

Bibliographic Details
Main Authors:	Wei Liu, Yan Xu, Yi Wang, Lugui Qiu, Ting Xie, Xiaojuan Wang, Huimin Liu, Tonghui Ma, Jianxiang Wang, Gang An, Weiwei Sui, Hesong Zou, Chunyang Wang, Chen Qiu, Dandan Shan, Wenyang Huang, Shuhua Yi, Dehui Zou
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/3/e008450.full

Similar Items

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
by: Wei Liu, et al.
Published: (2024-04-01)

P1162: FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA
by: Hesong Zou, et al.
Published: (2023-08-01)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
by: Yuting Yan, et al.
Published: (2023-07-01)

Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
by: Ying Yu, et al.
Published: (2024-01-01)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
by: Runxia Gu, et al.
Published: (2020-09-01)

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
by: Wenjie Xiong, et al.
Published: (2023-05-01)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
by: Ru Li, et al.
Published: (2023-04-01)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
by: Yan Zhang, et al.
Published: (2022-09-01)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
by: Chang Hong, et al.
Published: (2011-09-01)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
by: Wei Li, et al.
Published: (2023-05-01)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
by: Zhitao Ying, et al.
Published: (2021-02-01)

The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma
by: Huihsou Fan, et al.
Published: (2023-12-01)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023-01-01)

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
by: Hao Sun, et al.
Published: (2022-12-01)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
by: Yuankai Shi, et al.
Published: (2017-03-01)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
by: Wenjie Xiong, et al.
Published: (2023-05-01)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
by: Changju Qu, et al.
Published: (2022-08-01)

Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
by: Jingxian Gu, et al.
Published: (2022-03-01)

S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES
by: J. Yang, et al.
Published: (2022-06-01)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
by: Yi Wang, et al.
Published: (2023-08-01)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
by: Jie Zhao, et al.
Published: (2023-08-01)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
by: Yinqiang Zhang, et al.
Published: (2023-04-01)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
by: Jiaying Wu, et al.
Published: (2022-05-01)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01)

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
by: Yi Li Jiang, et al.
Published: (2024-02-01)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
by: Chunrui Li, et al.
Published: (2021-03-01)

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
by: Wenjie Zhang, et al.
Published: (2024-04-01)

Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
by: Shuhua Yi, et al.
Published: (2020-01-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
by: Keshu Zhou, et al.
Published: (2021-10-01)

450 Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome
by: Yifan Zhai, et al.
Published: (2021-11-01)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
by: Lanlan Zhou, et al.
Published: (2022-10-01)

CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human studyResearch in context
by: Xibin Xiao, et al.
Published: (2024-04-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Patients with relapsed/refractory hairy‐cell leukemia
by: Jérôme Paillassa, et al.
Published: (2022-03-01)

P867: CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1)
by: Chunrui LI, et al.
Published: (2023-08-01)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
by: Junfang Yang, et al.
Published: (2023-08-01)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
by: Weiping Liu, et al.
Published: (2021-11-01)